<DOC>
	<DOCNO>NCT00195754</DOCNO>
	<brief_summary>The purpose study determine long-term treatment , 1 year , Depakote ER safe reduction occurrence migraine headaches adolescent .</brief_summary>
	<brief_title>A Phase III Open-Label , Multi-Center , Long-Term Extension Study Depakote ER Subjects Who Either Completed Prematurely Discontinued Due Ineffectiveness From Study M02-488 .</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Subject subject 's legal representative voluntarily sign date IRBapproved informed assent form IRBapproved inform consent form , respectively , studyspecific procedure test perform ; The subject randomize Study M02488 either complete study prematurely discontinue due ineffectiveness ; The subject male nonpregnant , nonlactating female Exclusion Criteria Female , childbearing potential , use effective method birth control ( e.g. , total sexual abstinence contraceptive ) . Experienced serious adverse event Study M02488 investigator consider `` possibly '' `` probably relate '' study drug ; In investigator 's opinion , longterm treatment Depakote ER migraine prophylaxis contraindicate . For reason , subject consider investigator unsuitable candidate receive divalproex sodium participate study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Migraines</keyword>
	<keyword>Depakote ER</keyword>
	<keyword>divalproex sodium</keyword>
</DOC>